AndrewSloanMD

Brain & Spinal Tumor, Neurosurgical Spine Surgery, Pituitary Surgery

Professor & Vice-Chair of Neurological Surgery; Peter D. Cristal Chair of Neurosurgical Oncology; Director, Center for Brain Tumor & Neuro-Oncology; Director, Center of Excellence in Translational Neuro-Oncology; University Hospitals & Seidman Cancer Center Case Comprehensive Cancer Center, & Case Western Reserve University School of Medicine

Join to view full profile

Dr. Sloan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Sloan's full profile

Already have an account?

Office
2001 Peachtree Rd NE
Ste 645
Atlanta, GA 30309
Phone+1 404-605-2050

Fax+1 216-844-3014

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Neurological Surgery, 1990 - 1997
Harvard Medical SchoolClass of 1990

Certifications & Licensure

GA State Medical License 2022 - 2026
MI State Medical License 1998 - 2026
OH State Medical License 2006 - 2026
CA State Medical License 1992 - 2025
FL State Medical License 2004 - 2024
American Board of Neurological Surgery Neurological Surgery

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
Whos Who in Medicine and Healthcare Marquis Whos Who
Fellow (FACS) American College of Surgeons
Fellow (FAANS) American Association of Neurological Surgeons
Join now to see all

Clinical Trials

Biological Therapy Following Surgery and Radiation Therapy in Treating Patients With Primary or Recurrent Astrocytoma or Oligodendroglioma Start of enrollment: 1997 Jun 01
Completed
Phase 2
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer Start of enrollment: 2006 Dec 01
Active, not recruiting
Phase 3
Safety & Radiation Distribution Study of Cotara® in Patients With Recurrent Glioblastoma Multiforme Start of enrollment: 2006 Nov 01
Completed
Phase 1
Monteris AutoLITT™ FIM Safety Trial for Recurrent/Progressive Brain Tumors Start of enrollment: 2008 Aug 01
Completed
Phase 1
Imaging Procedure Using ALA in Finding Residual Tumor in Grade IV Malignant Astrocytoma Start of enrollment: 2009 Dec 08
Completed
Phase 2
BG & TMZ Therapy of Glioblastoma Multiforme Start of enrollment: 2011 Nov 22
Completed
Phase 1
A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma Start of enrollment: 2011 Dec 01
Completed
Phase 2
A Phase II Study of Oral LDE225 in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB) Start of enrollment: 2013 May 06
Completed
Phase 2
Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery Start of enrollment: 2013 May 01
Terminated
Phase 2
Laser Interstitial Thermotherapy (LITT) Combined With Checkpoint Inhibitor for Recurrent GBM (RGBM) Start of enrollment: 2017 Nov 29
Recruiting
Phase 1, Phase 2
LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent Glioblastoma Start of enrollment: 2020 Oct 21
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

Machine Learning-based Prognostic Subgrouping of Glioblastoma: A Multi-center Study.
Hamed Akbari, Spyridon Bakas, Chiharu Sako, Anahita Fathi Kazerooni, Javier Villanueva-Meyer
Neuro-Oncology. 2024-12-12
Validation and next-generation update of a DNA methylation-based recurrence predictor for meningioma: a multicenter prospective study.
Alexander P Landry, Justin Z Wang, Vikas Patil, Chloe Gui, Mamatjan Yasin
Neuro-Oncology. 2024-11-06
1 citations
Molecular classification to refine surgical and radiotherapeutic decision-making in meningioma.
Justin Z Wang, Vikas Patil, Alexander P Landry, Chloe Gui, Andrew Ajisebutu
Nature Medicine. 2024-11-01

Lectures

Phase I/II study of laser interstitial thermotherapy (LITT) combined with checkpoint inhibitor for recurrent glioblastoma (rGBM).
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
NRG BN002: Phase I study of checkpoint inhibitors anti-CTLA-4, anti-PD-1, the combination in patients with newly diagnosed glioblastoma.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

Immunotherapy Response Linked to Low TMB in Recurrent GlioblastomaJanuary 20th, 2021
Medtronic Selects UH Cleveland Medical Center for Stealth Autoguide Precision Robotic Platform for Brain SurgeryNovember 11th, 2020
Bevacizumab for the Treatment of Non-Small Cell Lung Cancer Patients with Synchronous Brain MetastasesNovember 28th, 2019
Join now to see all